查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856777

急性缺血性脑中风诊断市场（按产品类型、检测类型、疾病类型、技术和最终用户划分）－2025-2032年全球预测

Acute Ischemic Stroke Diagnosis Market by Product Type, Test Type, Disease Type, Technology, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，急性缺血性脑中风诊断市场规模将达到 64.7 亿美元，复合年增长率为 6.98%。

关键市场统计数据
基准年 2024 37.7亿美元
预计年份：2025年 39.9亿美元
预测年份 2032 64.7亿美元
复合年增长率 (%) 6.98%

明确紧迫的临床优先事项和技术驱动因素，以重塑急性缺血性脑中风的诊断并为策略决策提供依据

急性缺血性脑中风仍然是全球范围内导致发病率和死亡率的主要原因之一，因此需要快速、实证的诊断策略来优化临床疗效。新的生物标记、先进的影像学技术和床边诊断解决方案正在整合到时间紧迫的诊断领域，以缩短诊断时间并实现更有针对性的干预。随着临床团队不断完善分流通讯协定，院前识别、院内诊断和介入准备之间的相互作用对于降低残疾率和改善康復进程至关重要。

随着人们对个人化医疗的期望日益增长，诊断领域的相关人员必须权衡速度、准确性和资源投入。影像和实验室诊断技术的进步拓展了临床医生可用的工具，但也带来了采购、培训和工作流程整合的复杂性。因此，医疗机构领导者和临床主任面临着投资优先事项的决策，这些决策将直接影响患者就诊量、治疗时间长度和跨部门协作。以下章节概述了正在影响急性缺血性脑中风诊断的技术、政策和实践方面的关键转变，并重点介绍了医疗系统、设备製造商和诊断实验室需要考虑的策略因素。

探索正在加速诊断和重塑急性缺血性脑中风管理的关键技术进步和护理路径创新

由于技术进步、流程优化以及以速度和准确性为优先的新型诊疗模式的出现，急性缺血性脑中风的诊断格局正在发生显着变化。诸如快速CT灌注通讯协定和增强型MRI序列等先进影像技术正日益融入超急性期诊疗流程，用于区分胼胝体组织与不可逆损伤区域，并为再灌注治疗决策提供依据。同时，可携式影像设备和远端医疗平台已将诊断范围扩展至偏远地区，使远距专家能够指导时间紧迫的干预措施。

同时，分子诊断和血液生物标记正从研究领域走向临床应用，有望对病因进行分层，并识别出哪些患者对特定的再灌注策略无效。床边检测技术正在缩短关键参数的周转时间，并支援在急诊和院前救护环境中更早做出临床决策。这些技术进步，加上诸如直接进行CT分流、移动中风单位和简化传输通讯协定等诊疗路径的创新，旨在缩短从入院到溶栓治疗以及从入院到腹股沟穿刺的时间间隔。这些转变提高了诊断准确性，并释放了以患者为中心、循证的急性中风治疗的潜力。

评估海关制度的变化和跨境贸易的复杂性如何影响急性中风诊断的筹资策略和供应链韧性

关税政策和跨境贸易动态的变化会对用于急性缺血性脑中风诊断的诊断设备和耗材的供应和成本结构产生重大影响。 2025年，不断增加的关税压力衝击了医疗影像组件、实验室试剂和特殊耗材的供应链，迫使采购团队重新评估供应商关係和筹资策略。因此，医疗机构寻求供应链多元化，并提高关键物资的库存弹性，以避免重症患者的医疗服务中断。

这项转变促使医疗服务提供者和诊断试剂供应商重新评估总到岸成本，并探索其他采购方式，例如区域製造伙伴关係和一体化采购框架。临床医生和管理人员必须权衡短期成本上涨的可能性与维持快速诊断吞吐量的临床需求，因为这直接影响患者的治疗效果。为此，一些医疗系统优先考虑减少对进口耗材依赖的资本投资，而另一些系统则透过谈判达成长期供应协议来稳定价格并确保医疗服务的连续性。整体而言，关税相关的不利因素促使供应链管理采取更具策略性的方法，并加速考虑本地生产和冗余计画。

整合产品、测试、疾病、技术和最终用户观点，以识别差异化的采用路径和临床效用驱动因素。

透过多角度细分市场，可以揭示不同的临床和营运需求如何驱动需求和应用模式。依产品类型划分，诊断路径包括血液生物标记检测、颈动脉超音波、电脑断层扫描（CT）和磁振造影（MRI）等影像学检查以及脑电图（EEG），每种方法都发挥互补作用，从快速分诊到病因分类均有涉及。按检测类型划分，临床工作流程依赖实验室检测和代谢指标检测，其中包括血液检测和影像学评估，这些检测有助于选择急性治疗方案。按疾病类型划分，栓塞性中风、腔隙性中风和血栓性中风的诊断重点各不相同，因为每种病理对影像学选择、生物标记解读和二级预防策略都有其独特的影响。按技术划分，检测工具涵盖基于生物标记的检测和就地检验平台，它们的周转时间、所需基础设施和操作人员培训各不相同。在最终用户中，门诊手术中心、诊断中心、医院/诊所和实验室将根据不同的使用情况、监管限制和临床期望做出采用和采购决定。

整合这种细分观点，有助于相关人员根据不同使用者类型和疾病特征的具体需求，调整产品开发、临床检验和商业化策略。例如，针对照护现场优化的解决方案优先考虑快速週转和简化的工作流程，而影像技术投资则侧重于吞吐量、与卒中诊疗方案的兼容性以及与介入团队的整合。这种多维度的观点有助于在各种临床环境中进行有针对性的创新和更有效的部署。

检验基础设施、临床通讯协定和实施动态方面的区域差异，以便在不同的医疗环境中製定相应的诊断策略。

区域动态对急性缺血性脑中风的诊断方法应用、基础设施投资和临床方案有显着影响。在美洲，先进的三级医疗中心和综合医疗网络主导高端影像、移动卒中单元和生物标誌物研究的应用，而同一区域内的农村地区仍然面临着远端医疗匮乏的挑战，因此需要远距医疗和中心辐射式医疗模式。在欧洲、中东和非洲，医疗体系各不相同，一方面是都市区地区，这些地区以卓越的医疗水平为导向，并得到公共卫生倡议的支持，重点发展卒中网络；另一方面是资源匮乏的地区，这些地区需要切实可行、可扩展的诊断解决方案。在亚太地区，医疗基础设施的快速现代化和对诊断影像的大量投资正在扩大医疗能力，但报销机制和医护人员配备的差异导致先进诊断技术的应用并不均衡。

这些区域差异会影响供应商在监管核准、本地化服务模式以及与卫生署的伙伴关係所采取的优先顺序。此外，疾病流行模式、急救医疗服务的成熟度以及当地的培训计画也会影响采用先进诊断工作流程的可行性。因此，企业和医疗系统必须制定量身定制的策略，充分考虑基础设施的成熟度、临床实践规范以及不同环境下医护人员和患者的实际需求。

分析竞争格局，看整合影像、快速侦测和软体驱动的工作流程如何重新定义诊断差异化。

在急性缺血性脑中风诊断领域，主要企业正致力于推广差异化的产品组合，包括影像硬体、实验室检测、照护现场平台和整合软体解决方案。同时，创新参与企业则专注于生物标记发现、快速检测以及用于急诊和院前急救的微型诊断设备。影像设备供应商、检测开发人员和临床机构之间的伙伴关係日益普遍，从而能够协同开发整合诊断路径，加速临床检验和应用。

竞争也反映了规模与专业化之间的平衡。大型製造商利用其全球服务网路和已建立的安装基础，销售整合扫描器、资讯学和培训的捆绑式解决方案。同时，灵活的新兴企业通常专注于特定领域的性能优势，例如超快速检测或人工智慧影像分析，并致力于透过有针对性的临床试验和策略联盟来证明其临床疗效。总体而言，竞争格局奖励互通性、对监管的积极洞察以及在诊断时间和准确性方面取得显着改进，从而为整合和策略联盟创造了机会。

为开发者和医疗保健领导者提供可操作的策略重点，以加速产品应用并确保持续的临床和商业性优势。

产业领导者应采取一系列切实可行的优先事项，在控制营运风险的同时，加速临床应用。首先，透过投资互通性、以使用者为中心的设计以及减少实施阻力的培训项目，使产品开发与实际临床工作流程保持一致。其次，优先进行能够显着缩短诊断时间和改善治疗方案选择的临床检验研究，从而增强对支付者和医院的提案主张。第三，透过实现生产和销售管道多元化，并谈判签订稳定的合约以确保关键组件和试剂的供应，从而解决供应链脆弱性问题。

此外，医疗机构应儘早与支付方和监管相关人员接洽，明确报销途径，并规划符合证据要求的试验。与急救医疗服务机构、区域中风网路和学术中心进行策略合作，可以加速技术应用，并产生可靠的临床数据。最后，医疗机构可以投资于可扩展的服务模式和管理式产品，以降低医疗系统的整体拥有成本，并考虑有针对性的商业化策略，根据最终用户的能力对产品进行分级。这些措施的综合运用，既能提升市场相关性，又能帮助临床医师更快、更准确地诊断中风。

采用严谨的多来源调查方法，结合临床证据、专家见解和供应链分析，得出可靠的结论。

调查方法采用多源整合策略，结合临床文献回顾、专家访谈、技术评估和供应链分析，以全面展现诊断现况。证据综合分析采用同侪审查的临床研究、指南声明和已发表的技术评估报告，以评估临床效用和对工作流程的影响。透过对神经科、急诊科医生、放射科医生、实验室主任和采购负责人的访谈，揭示了实际操作中的限制因素和推广应用的驱动因素；同时，供应商的演示和产品数据表则提供了设备功能和服务模式的技术背景。

我们的供应链和政策分析依赖海关和贸易文件、采购竞标资讯以及公共部门政策公告，以评估影响设备和试剂供应的因素。在适当情况下，我们借鉴了高绩效卒中中心的案例，以阐明路径重建和技术整合的最佳实践。在整个调查方法中，我们整合了多个资讯流，以确保我们的结论能够反映与急性缺血性脑中风诊断相关的临床实际情况、运作限制和技术发展轨迹。

急性中风诊断有效性和患者预后受临床、技术和操作因素共同影响的总结

总之，急性缺血性中风诊断正处于曲折点，技术创新、流程重塑和供应链考量正在汇聚，共同重塑临床实践。快速成像、新型生物标记应用和就地检验能够实现更准确、更及时的决策，而区域和政策因素则影响这些技术的应用可能性和速度。积极主动地解决工作流程整合、临床检验和采购弹性等问题的相关人员，将更有能力把诊断技术的进步转化为病患预后的可衡量改善。

展望未来，持续专注于缩短治疗时间，并持续提高诊断准确性，将继续推动临床、商业和政策领域的投资与合作。注重互通性、实证严谨性和适应性交付策略，将使医疗服务提供者和产业合作伙伴能够确保下一代诊断工具在急性缺血性脑中风治疗中既具有临床价值，又具有营运永续性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过整合以人工智慧为基础的CT灌注分析加速急性缺血性脑中风的诊断和分诊
  • 部署配备可携式CT扫描仪和远端医疗连接的移动卒中单元，以缩短从入院到接受治疗的时间。
  • 利用基于血液的生物标记组合结合人工智慧演算法快速区分缺血性卒中亚型
  • 利用云端基础的影像诊断平台扩展远距中风网络，改善农村地区急性中风患者的治疗效果
  • 用于即时检测缺血性中风患者神经发炎标记的照护现场分子检测技术取得了进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型分類的急性缺血性脑中风诊断市场

  • 血液生物标记
  • 颈动脉超音波
  • 影像诊断
    • 电脑断层扫描（CT）扫描仪
    • 磁振造影系统
  • 脑电图（EEG）

第九章 依侦测类型急性缺血性脑中风诊断市场

  • 实验室检测
    • 血液检查
    • 影像检查
  • 代谢指标

第十章 依疾病类型分類的急性缺血性脑中风诊断市场

  • 栓塞
  • 空白
  • 血栓性

第十一章急性缺血性脑中风诊断市场（依技术划分）

  • 基于生物标记的检测
  • 就地检验

第十二章急性缺血性脑中风诊断市场（依最终用户划分）

  • 门诊手术中心
  • 诊断中心
  • 医院和诊所
  • 研究所

第十三章急性缺血性脑中风诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章急性缺血性脑中风诊断市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国急性缺血性脑中风诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Aidoc Medical Ltd.
    • BIOTRONIK SE & Co KG
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corporation
    • Canon Medical Systems Corporation
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • GE Healthcare Technologies Inc.
    • Hitachi, Ltd.
    • Integral Diagnostics（IDX）Group
    • Johnson & Johnson Services, Inc.
    • Koninklijke Philips NV
    • Mediso Ltd.
    • Medtronic PLC
    • Merck & Co.
    • Neusoft Corporation
    • Nihon Kohden Corporation
    • Planmed Oy
    • Samsung Electronics Co. Ltd.
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Shimadzu Corporation
    • Shionogi & Co., Ltd.
    • Siemens Healthineers
    • Stryker Corporation
    • Toshiba International Corporation
Product Code: MRR-B16853776EA8

The Acute Ischemic Stroke Diagnosis Market is projected to grow by USD 6.47 billion at a CAGR of 6.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.77 billion
Estimated Year [2025] USD 3.99 billion
Forecast Year [2032] USD 6.47 billion
CAGR (%) 6.98%

Framing the urgent clinical priorities and technological drivers reshaping acute ischemic stroke diagnosis to inform strategic decision-making

Acute ischemic stroke remains a leading cause of morbidity and mortality worldwide and demands rapid, evidence-based diagnostic strategies to optimize clinical outcomes. The diagnostic landscape is evolving as time-critical pathways integrate novel biomarkers, advanced imaging modalities, and point-of-care solutions that shorten time-to-diagnosis and enable more targeted interventions. As clinical teams refine triage protocols, the interplay between pre-hospital recognition, in-hospital diagnostics, and interventional readiness has become central to reducing disability and improving recovery trajectories.

In the context of rising expectations for personalized care, diagnostic stakeholders must balance speed, accuracy, and resource intensity. Technological advances in imaging and laboratory diagnostics have expanded the tools available to clinicians, but they also introduce complexity in procurement, training, and workflow integration. Consequently, institutional leaders and clinical directors face decisions about investment priorities that directly influence patient throughput, treatment windows, and cross-disciplinary collaboration. The subsequent sections synthesize the key shifts in technology, policy, and practice that are shaping acute ischemic stroke diagnosis and highlight strategic considerations for health systems, device manufacturers, and diagnostic laboratories.

Exploring the pivotal technological advancements and care pathway innovations that are accelerating diagnosis and reshaping acute ischemic stroke management

The landscape of acute ischemic stroke diagnosis is undergoing transformative shifts driven by technological refinement, operational redesign, and emerging care models that prioritize speed and precision. Advanced imaging techniques, such as rapid CT perfusion protocols and enhanced MRI sequences, are increasingly integrated into hyperacute workflows to differentiate penumbral tissue from irreversibly damaged areas, thereby informing reperfusion decisions. At the same time, portable imaging and telemedicine platforms have extended diagnostic reach into community and rural settings, enabling remote expertise to guide time-sensitive interventions.

Concurrently, molecular diagnostics and blood-based biomarkers are moving from research settings toward clinical applicability, offering the potential to stratify etiologies and identify patients unlikely to benefit from certain reperfusion strategies. Point-of-care testing technologies are reducing turnaround times for critical parameters and supporting earlier clinical decision-making in emergency and pre-hospital environments. These technological advances are coupled with care pathway innovations such as direct-to-CT triage, mobile stroke units, and streamlined transfer protocols, all of which seek to compress door-to-needle and door-to-groin puncture intervals. Together, these shifts enhance the precision of diagnosis and expand the possibilities for patient-centered, evidence-based acute stroke care.

Assessing how shifting tariff regimes and cross-border trade complexities have influenced procurement strategies and supply chain resilience in acute stroke diagnostics

Tariff policy changes and cross-border trade dynamics can materially influence the availability and cost structure of diagnostic equipment and consumables that support acute ischemic stroke diagnosis. In 2025, heightened tariff pressures affected the supply chains for medical imaging components, laboratory reagents, and specialized disposables, prompting procurement teams to reassess vendor relationships and sourcing strategies. As a result, organizations sought to diversify supply channels and to increase inventory resilience for critical items to avoid disruptions in hyperacute care delivery.

These shifts prompted healthcare providers and diagnostics suppliers to re-evaluate total landed costs and to explore alternative sourcing arrangements, including regional manufacturing partnerships and consolidated procurement frameworks. Clinicians and administrators had to balance the potential for short-term cost increases against the clinical imperative of maintaining rapid diagnostic throughput, which is directly tied to patient outcomes. In response, some systems prioritized capital investments that reduced dependency on imported consumables, while others negotiated long-term supply contracts to stabilize prices and ensure continuity of care. Overall, tariff-related headwinds encouraged a more strategic approach to supply chain management and accelerated considerations for localized production and redundancy planning.

Integrating product, test, disease, technology, and end-user perspectives to reveal differentiated adoption pathways and clinical utility drivers

Understanding the market through multiple segmentation lenses clarifies how distinct clinical and operational needs drive demand and adoption patterns. Based on product type, diagnostic pathways incorporate blood biomarker assays, carotid ultrasound, diagnostic imaging modalities including computed tomography scanners and MRI systems, and electroencephalography, each serving complementary roles from rapid triage to etiologic classification. Based on test type, the clinical workflow relies on lab tests and metabolic panels, with lab tests further encompassing blood tests and imaging-based assessments that inform acute therapeutic choices. Based on disease type, diagnostic priorities differ for embolic, lacunar, and thrombotic strokes, as each presentation carries unique implications for imaging selection, biomarker interpretation, and secondary prevention strategies. Based on technology, detection tools span biomarker-based assays and point-of-care testing platforms, which vary in turnaround time, required infrastructure, and operator training. Based on end-user, adoption and procurement decisions are driven by ambulatory surgical centers, diagnostic centers, hospitals and clinics, and research laboratories, each with distinct volume profiles, regulatory constraints, and clinical expectations.

By synthesizing these segmentation perspectives, stakeholders can align product development, clinical validation, and commercialization strategies with the specific needs of different user types and disease presentations. For example, solutions optimized for point-of-care use will prioritize rapid turnaround and simplified workflows, whereas imaging investments will focus on throughput, compatibility with stroke protocols, and integration with interventional teams. This multi-dimensional view supports targeted innovation and more effective deployment across diverse clinical settings.

Examining regional variations in infrastructure, clinical protocols, and adoption dynamics to align diagnostic strategies across diverse healthcare environments

Regional dynamics exert a profound influence on diagnostic adoption, infrastructure investment, and clinical protocols for acute ischemic stroke. In the Americas, advanced tertiary centers and integrated health networks often lead in deploying high-end imaging, mobile stroke units, and biomarker research, while rural regions within the same geography continue to face access challenges requiring telemedicine and hub-and-spoke models. In Europe, the Middle East & Africa, healthcare systems vary widely, with pockets of excellence in urban centers supported by public health initiatives that emphasize stroke networks, contrasted with areas where resource constraints necessitate pragmatic, scalable diagnostic solutions. In Asia-Pacific, rapid modernization of healthcare infrastructure and significant investments in imaging have expanded capacity, yet heterogeneity in reimbursement and workforce availability shapes differential uptake of advanced diagnostics.

These regional contrasts influence where vendors prioritize regulatory approvals, localization of service models, and partnerships with health ministries and hospital groups. Moreover, prevalence patterns, emergency medical services maturity, and regional training programs affect the feasibility of implementing advanced diagnostic workflows. Consequently, companies and health systems must craft regionally tailored strategies that consider infrastructure maturity, clinical practice norms, and the pragmatic needs of providers and patients across diverse settings.

Profiling the competitive landscape where integrated imaging, rapid assays, and software-enabled workflows converge to redefine diagnostic differentiation

Key companies competing in acute ischemic stroke diagnostics are advancing differentiated portfolios that span imaging hardware, laboratory assays, point-of-care platforms, and integrated software solutions. Market leaders complement established imaging platforms with software enhancements that improve workflow efficiency and quantitative interpretation, while innovative entrants concentrate on biomarker discovery, rapid assay formats, and compact diagnostic devices intended for emergency and pre-hospital use. Partnerships between imaging vendors, assay developers, and clinical institutions are increasingly common, enabling co-development of integrated diagnostic pathways that accelerate clinical validation and adoption.

Competitive dynamics also reflect a balance between scale and specialization. Large manufacturers leverage global service networks and established installation bases to sell bundled solutions that integrate scanners, informatics, and training. Meanwhile, agile startups often focus on niche performance advantages such as ultra-rapid assays or AI-enhanced image analysis, aiming to prove clinical impact through targeted trials and strategic collaborations. Overall, the competitive landscape rewards interoperability, regulatory foresight, and demonstrable improvements in diagnostic timelines and decision accuracy, creating opportunities for both consolidation and strategic alliances.

Actionable strategic priorities for developers and healthcare leaders to accelerate adoption and secure durable clinical and commercial advantages

Industry leaders should pursue a set of actionable priorities that accelerate clinical impact while managing operational risk. First, align product development with real-world clinical workflows by investing in interoperability, user-centered design, and training programs that reduce adoption friction. Second, prioritize clinical validation studies that demonstrate meaningful reductions in diagnostic time and improvements in treatment selection, thereby strengthening value propositions for payers and hospitals. Third, address supply chain vulnerabilities by diversifying manufacturing and distribution channels and by negotiating stable agreements that preserve access to critical components and reagents.

Furthermore, organizations should engage payer and regulatory stakeholders early to clarify reimbursement pathways and to design studies that meet evidentiary expectations. Strategic collaborations with emergency medical services, regional stroke networks, and academic centers can accelerate adoption and generate robust clinical data. Finally, invest in scalable service models and managed offerings that reduce total cost of ownership for health systems, and consider targeted commercialization strategies that match product tiering to the capacities of different end-users. Taken together, these actions will enhance market relevance while supporting clinicians in delivering faster, more accurate stroke diagnosis.

Describing a rigorous multi-source research approach combining clinical evidence, expert insights, and supply chain analysis to support robust conclusions

The research methodology integrates a multi-source approach combining clinical literature review, expert interviews, technology assessments, and supply chain analysis to produce a holistic view of the diagnostic landscape. Evidence synthesis draws on peer-reviewed clinical studies, guideline statements, and published technology evaluations to assess clinical utility and workflow implications. Interviews with neurologists, emergency physicians, radiologists, laboratory directors, and procurement leaders informed practical constraints and adoption drivers, while vendor briefings and product datasheets provided technical context on device capabilities and service models.

Supply chain and policy analyses relied on customs and trade documentation, procurement tender information, and public sector policy announcements to evaluate factors affecting equipment and reagent availability. Where appropriate, case examples from high-performance stroke centers illustrated best practices in pathway redesign and technology integration. Throughout the methodology, triangulation of multiple information streams ensured that conclusions reflect clinical realities, operational constraints, and technological trajectories relevant to acute ischemic stroke diagnosis.

Summarizing the converging clinical, technological, and operational forces that will determine diagnostic effectiveness and patient outcomes in acute stroke

In conclusion, acute ischemic stroke diagnosis is at an inflection point where technological innovation, pathway redesign, and supply chain considerations converge to reshape clinical practice. Rapid imaging, emergent biomarker applications, and point-of-care testing collectively enable more precise and timely decision-making, while regional and policy factors influence the feasibility and pace of adoption. Stakeholders who proactively address workflow integration, clinical validation, and procurement resilience will be best positioned to translate diagnostic advances into measurable improvements in patient outcomes.

Looking forward, the sustained focus on reducing time-to-treatment, combined with iterative improvements in diagnostic accuracy, will continue to drive investment and collaboration across clinical, commercial, and policy domains. By emphasizing interoperability, evidentiary rigor, and adaptive supply strategies, healthcare providers and industry partners can ensure that the next generation of diagnostic tools delivers both clinical value and operational sustainability for acute ischemic stroke care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-powered CT perfusion analysis to accelerate acute ischemic stroke diagnosis and triage
  • 5.2. Deployment of mobile stroke units equipped with portable CT scanners and telemedicine connectivity to reduce door-to-needle times
  • 5.3. Adoption of blood-based biomarker panels combined with AI algorithms for rapid differentiation of ischemic stroke subtypes
  • 5.4. Expansion of telestroke networks leveraging cloud-based imaging platforms to improve rural acute stroke patient outcomes
  • 5.5. Advancement in point-of-care molecular assays for real-time detection of neuroinflammatory markers in ischemic stroke patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Ischemic Stroke Diagnosis Market, by Product Type

  • 8.1. Blood Biomarker
  • 8.2. Carotid Ultrasound
  • 8.3. Diagnostic Imaging
    • 8.3.1. Computed Tomography (CT) Scanner
    • 8.3.2. MRI System
  • 8.4. Electroencephalography

9. Acute Ischemic Stroke Diagnosis Market, by Test Type

  • 9.1. Lab Tests
    • 9.1.1. Blood Test
    • 9.1.2. Imaging Tests
  • 9.2. Metabolic Panel

10. Acute Ischemic Stroke Diagnosis Market, by Disease Type

  • 10.1. Embolic
  • 10.2. Lacunar
  • 10.3. Thrombotic

11. Acute Ischemic Stroke Diagnosis Market, by Technology

  • 11.1. Biomarker-Based Detection
  • 11.2. Point Of Care Testing

12. Acute Ischemic Stroke Diagnosis Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals & Clinics
  • 12.4. Research Laboratories

13. Acute Ischemic Stroke Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Ischemic Stroke Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Ischemic Stroke Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Aidoc Medical Ltd.
    • 16.3.3. BIOTRONIK SE & Co KG
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Boston Scientific Corporation
    • 16.3.6. Canon Medical Systems Corporation
    • 16.3.7. F. Hoffmann-La Roche Ltd.
    • 16.3.8. Fujifilm Holdings Corporation
    • 16.3.9. GE Healthcare Technologies Inc.
    • 16.3.10. Hitachi, Ltd.
    • 16.3.11. Integral Diagnostics (IDX) Group
    • 16.3.12. Johnson & Johnson Services, Inc.
    • 16.3.13. Koninklijke Philips N.V.
    • 16.3.14. Mediso Ltd.
    • 16.3.15. Medtronic PLC
    • 16.3.16. Merck & Co.
    • 16.3.17. Neusoft Corporation
    • 16.3.18. Nihon Kohden Corporation
    • 16.3.19. Planmed Oy
    • 16.3.20. Samsung Electronics Co. Ltd.
    • 16.3.21. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 16.3.22. Shimadzu Corporation
    • 16.3.23. Shionogi & Co., Ltd.
    • 16.3.24. Siemens Healthineers
    • 16.3.25. Stryker Corporation
    • 16.3.26. Toshiba International Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 281. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 286. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 287. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 290. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 291. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 296. GCC ACUTE ISCHEMIC STROKE DI